Medicare Enrolled
Dr. Anita Tharian, DO
Internal Medicine · Mesquite, TX
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Tharian from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Tharian?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Tharian
Dr. Anita Tharian is an internal medicine specialist in Mesquite, TX, with 20 years of NPI registration. Based on federal Medicare data, Dr. Tharian performed 37,980 Medicare services in 2023. These records do not provide a deduplicated patient total.
Between the years covered by Open Payments, Dr. Tharian received a total of $10,217 from 88 pharmaceutical and/or device companies across 529 payment records. A record can group multiple payments. These transfers are publicly reported through CMS Open Payments. Disclosure alone does not establish their effect on care. A reliable breakdown by payment category is not available in this snapshot. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Tharian is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 20 years of NPI registration
▲ Top 1% volume in TX
$10,217 industry payments
Medicare Practice Summary — 2023
Medicare Utilization ↗37,980
Medicare services
Top 1% in TX for internal medicine
Not available
Unique patients (not deduplicated)
$25
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Iron infusion (Feraheme) An injection of ferumoxytol used to treat iron deficiency anemia in patients not on dialysis. |
24,480 | $0 | $2 |
| Denosumab injection (Prolia/Xgeva) | 5,041 | $18 | $64 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
2,652 | $0 | $1 |
| Anti-nausea injection (ondansetron/Zofran) | 2,201 | $0 | $1 |
| Piflufolastat F-18 diagnostic injection A diagnostic injection of the radioactive tracer piflufolastat F-18 used for imaging. The dose specified is 1 millicurie. |
845 | $475 | $1,376 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
479 | $23 | $105 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
276 | $102 | $430 |
| Nuclear medicine scan from skull base to mid-thigh with CT A nuclear medicine imaging study covering the area from the base of the skull to the middle of the thighs, performed alongside a CT scan. |
203 | $1,233 | $6,313 |
| 3D screening mammography (tomosynthesis) A screening imaging test of the breast using 3D technology to detect potential abnormalities. |
167 | $51 | $200 |
| Screening mammography An X-ray of the breast used to detect breast cancer in women who have no signs or symptoms of the disease. |
166 | $125 | $488 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
166 | $10 | $44 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
144 | $66 | $280 |
| Office visit, established patient (10-19 min) An office visit for an existing patient lasting 10 to 19 minutes. The visit involves medical evaluation and management of the patient's condition. |
137 | $40 | $205 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
130 | $1 | $2 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
120 | $100 | $291 |
| Intravenous infusion of new drug or substance, 1 hour or less This procedure involves administering a new medication or substance directly into a vein through an existing access site. The infusion is completed within one hour or less. |
105 | $52 | $208 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
104 | $140 | $427 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 99 | $99 | $433 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
74 | $47 | $223 |
| Unclassified drug A medication that does not fit into standard HCPCS or CPT classification categories. |
72 | $4 | $7 |
| Digital breast tomosynthesis (3D mammogram) A specialized imaging test that creates three-dimensional pictures of the breast tissue to help detect abnormalities. |
57 | $34 | $200 |
| Bone density scan (DEXA) A test that uses low-dose X-rays to measure bone mineral density in the hip, pelvis, and spine. It helps assess bone strength and risk of fractures. |
43 | $31 | $101 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
40 | $125 | $437 |
| Diagnostic mammography of 1 breast An X-ray examination of one breast to evaluate specific breast symptoms or abnormalities. |
34 | $72 | $476 |
| Whole body nuclear medicine scan with CT A combined imaging procedure using nuclear medicine and CT scans to visualize the entire body. |
29 | $1,231 | $6,502 |
| Limited ultrasound of 1 breast A focused ultrasound examination of a single breast to evaluate specific areas of concern. |
28 | $64 | $303 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
28 | $23 | $80 |
| Diagnostic mammography of both breasts | 23 | $70 | $603 |
| New patient office visit (30-44 min) An initial office visit for a new patient lasting between 30 and 44 minutes. This code is used when the total time spent on the date of the encounter falls within this range. |
21 | $80 | $406 |
| Complete breast ultrasound, 1 breast A complete ultrasound examination of one breast to visualize internal structures. |
16 | $81 | $316 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. These counts do not measure clinical quality or years of experience.
66.9% high complexity
29.9% medium
3.2% routine
Industry Payment Transparency
Open Payments through 2024 ↗$10,217
Total received (2018-2024)
Avg $1,460/year across 7 years
Top 9% in TX for internal medicine
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
88
Companies
529
Payment records
Payments are publicly reported; disclosure does not establish legality · Not evidence of wrongdoing · How to interpret →
Payment categories are unavailable while the source breakdown is being rebuilt. Company and year totals do not identify how much belongs to each category.
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$950
2023
$2,011
2022
$2,082
2021
$1,052
2020
$751
2019
$1,819
2018
$1,552
Payments by company (2024)
Astellas Pharma US Inc
$101
GlaxoSmithKline, LLC.
$72
PharmaEssentia USA Corporation
$68
PFIZER INC.
$60
ABBVIE INC.
$52
AstraZeneca Pharmaceuticals LP
$49
Regeneron Healthcare Solutions, Inc.
$49
E.R. Squibb & Sons, L.L.C.
$46
Novartis Pharmaceuticals Corporation
$42
Gilead Sciences, Inc.
$40
Dendreon Pharmaceuticals LLC
$34
Rigel Pharmaceuticals, Inc.
$34
Boehringer Ingelheim Pharmaceuticals, Inc.
$31
Sumitomo Pharma America, Inc.
$28
Merck Sharp & Dohme LLC
$28
GENZYME CORPORATION
$27
SOBI, INC
$25
Amneal Pharmaceuticals LLC
$25
Amgen Inc.
$24
Bayer Healthcare Pharmaceuticals Inc.
$23
Tempus AI, Inc
$21
Genentech USA, Inc.
$20
Olympus America Inc.
$17
Secura Bio, Inc.
$17
Mirati Therapeutics, Inc.
$16
Top 3 companies account for 25.4% of 2024 payments
All-time payments by company (2018-2024) ›
Novartis Pharmaceuticals Corporation
$998
E.R. Squibb & Sons, L.L.C.
$706
PFIZER INC.
$601
Celgene Corporation
$439
Amgen Inc.
$411
Astellas Pharma US Inc
$389
Genentech USA, Inc.
$362
AstraZeneca Pharmaceuticals LP
$356
Merck Sharp & Dohme Corporation
$316
GlaxoSmithKline, LLC.
$303
Rigel Pharmaceuticals, Inc.
$283
NOVARTIS PHARMACEUTICALS CORPORATION
$283
Regeneron Healthcare Solutions, Inc.
$253
Incyte Corporation
$247
Gilead Sciences, Inc.
$222
GENZYME CORPORATION
$155
Acrotech Biopharma LLC
$151
Cumberland Pharmaceuticals, Inc.
$143
Janssen Biotech, Inc.
$137
Pharmacyclics LLC, An AbbVie Company
$135
Tactile Systems Technology Inc
$134
TESARO, Inc.
$131
Clovis Oncology, Inc.
$129
Boehringer Ingelheim Pharmaceuticals, Inc.
$123
Bayer HealthCare Pharmaceuticals Inc.
$113
Takeda Pharmaceuticals U.S.A., Inc.
$112
EMD Serono, Inc.
$103
Merck Sharp & Dohme LLC
$102
Taiho Oncology, Inc.
$96
PharmaEssentia USA Corporation
$92
Lilly USA, LLC
$91
Ipsen Biopharmaceuticals, Inc
$86
Janssen Pharmaceuticals, Inc
$81
ARRAY BIOPHARMA INC
$79
Seagen Inc.
$78
Kyowa Kirin, Inc.
$74
Sirtex Medical Inc
$68
Puma Biotechnology, Inc.
$67
Amneal Pharmaceuticals LLC
$65
Bayer Healthcare Pharmaceuticals Inc.
$62
Eisai Inc.
$60
Blueprint Medicines Corporation
$55
Epizyme, Inc.,
$55
Kite Pharma, Inc.
$54
Dova Pharmaceuticals
$54
Coherus Biosciences Inc.
$53
Dendreon Pharmaceuticals LLC
$53
ABBVIE INC.
$52
Advanced Accelerator Applications
$48
EISAI INC.
$46
Teva Pharmaceuticals USA, Inc.
$46
Organon LLC
$45
Genmab U.S., Inc.
$39
CTI BioPharma Corp.
$38
Octapharma USA, Inc.
$38
AbbVie, Inc.
$37
Alexion Pharmaceuticals, Inc.
$33
Sun Pharmaceutical Industries Inc.
$30
Daiichi Sankyo Inc.
$29
Lexicon Pharmaceuticals, Inc.
$29
Pharmacosmos Therapeutics Inc.
$29
Sumitomo Pharma America, Inc.
$28
Verastem, Inc.
$28
MEDIVATION FIELD SOLUTIONS LLC
$27
SOBI, INC
$25
Stemline Therapeutics Inc.
$24
Exelixis Inc.
$23
TerSera Therapeutics LLC
$23
Tempus AI, Inc
$21
Spectrum Pharmaceuticals Inc.
$21
Adaptive Biotechnologies Corporation
$20
BeiGene USA, Inc.
$19
GE HealthCare
$19
G1 Therapeutics, Inc.
$18
Blue Earth Diagnostics Limited
$18
Olympus America Inc.
$17
Sobi, Inc
$17
Secura Bio, Inc.
$17
MorphoSys, US Inc.
$17
Karyopharm Therapeutics Inc.
$17
Mylan Institutional Inc.
$17
PUMA BIOTECHNOLOGY, INC.
$16
Mirati Therapeutics, Inc.
$16
Deciphera Pharmaceuticals Inc.
$15
Medtronic USA, Inc.
$14
AMAG Pharmaceuticals, Inc.
$14
Acrotech Biopharma Inc.
$14
Seattle Genetics, Inc.
$11
Top 3 companies account for 22.6% of all-time payments
Associated products mentioned in payments ›
ADCETRIS · AFINITOR · ALIMTA · ALUNBRIG · AVASTIN · AYVAKIT · Abraxane · Alecensa · Aliqopa · Avastin · Axumin · BAVENCIO · BELEODAQ · BENDEKA · BESREMI · BLENREP · BOSULIF · BRAFTOVI · BRUKINSA · Bavencio · CALQUENCE · COPIKTRA · COSELA · CYRAMZA · Cabometyx · Copiktra · DARZALEX · DOPTELET · Doptelet · ELAHERE · ELIQUIS · ELITEK · EMEND · EMPLICITI · EPKINLY · ERLEADA · EVENITY · Enhertu · Epkinly · Erivedge · Erleada · FERAHEME · FLEXITOUCH · GAVRETO · GAZYVA · GILOTRIF · IBRANCE · IMBRUVICA · IMFINZI · INJECTAFER · INLYTA · INQOVI · INREBIC · Imbruvica · Inrebic · JADENU · JAKAFI · JEMPERLI · JEVTANA · KANJINTI · KEYTRUDA · KISQALI · KRAZATI · Kyprolis · LIBTAYO · LONSURF · LUMAKRAS · LUTATHERA · LYNPARZA · Lenvima · Lonsurf · Lutathera · MEKINIST · MONJUVI · MONOFERRIC · MVASI · NERLYNX · NINLARO · Nerlynx · Neulasta · Nexavar · Nplate · Nubeqa · OJJAARA · ONTRUZANT · OPDIVO · OPDUALAG · ORGOVYX · OSTEOCOOL RF ABLATION · Odomzo · Ogivri · Onivyde · Orserdu · PADCEV · PANZYGA · PIQRAY · PLUVICTO · POTELIGEO · PROMACTA · PROVENGE · Padcev · Perjeta · Phesgo · Pomalyst · QINLOCK · REBLOZYL · ROLVEDON · RYDAPT · Revlimid · Rezlidhia · Rubraca · SANCUSO · SANDOSTATIN · SANDOSTATIN LAR · SARCLISA · SIR-Spheres Microspheres · SOLIRIS · SOMATULINE DEPOT · SPRYCEL · SUTENT · Stivarga · TABRECTA · TAGRISSO · TASIGNA · TAZVERIK · TECENTRIQ · TEPMETKO · TUKYSA · Tavalisse · Tecentriq · Tivdak · Trodelvy · Udenyca · VENCLEXTA · VERZENIO · VOTRIENT · Venclexta · Vonjo · XALKORI · XARELTO · XPOVIO · XTANDI · Xermelo · Xofigo · Xospata · Xtandi · YERVOY · ZEJULA · ZOLADEX · iTIND System
Should you be concerned? Industry payments are disclosed through CMS Open Payments. Disclosure alone does not establish their purpose, legality, or effect on care. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Geographic Context
Internal medicine physicians in nearby ZIP areas
1,859
County median income
$74,149
Nearest hospital to ZIP centroid (approximate)
DALLAS REGIONAL MEDICAL CENTER
2.9 mi
2.9 mi
Data Sources
| Provider Registry | ✓ NPPES | NPPES snapshot; verify current record |
| Medicare Enrollment | ✓ PECOS | PECOS snapshot |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not included | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Tharian is a mixed practice specialist, with above-average Medicare volume (top 1% in TX), with 20 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Tharian experienced with iron infusion (feraheme)?
Based on Medicare claims data, Dr. Tharian performed 24,480 iron infusion (feraheme) services. These records cover Medicare fee-for-service activity, including eligible younger beneficiaries; they do not measure total practice volume or clinical quality.
Does Dr. Tharian receive payments from pharmaceutical companies?
Yes. Dr. Tharian received a total of $10,217 from 88 companies across 529 payment records. A record can group multiple payments. These transfers are publicly disclosed through CMS Open Payments. Disclosure alone does not establish their legality or effect on care. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Tharian's costs compare to other internal medicine physicians in Mesquite?
Dr. Tharian's average Medicare payment per service is $25. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Tharian) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating the presence of registry, enrollment, activity or payment records, not verified experience or clinical quality. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Source publication dates and the snapshots loaded on this site can differ. Rebuilding a page does not refresh its source records. Check the Medicare reporting year and the payment interval shown above; consult the linked official sources for newer releases and current registry details. See our data freshness policy →
Explore related providers
Same specialty & city
Internal Medicine Physicians in Mesquite
Browse internal medicine physicians in Mesquite ranked by procedure volume and transparency data.
Highest volume
Top Internal Medicine Physicians in TX
Internal medicine physicians ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Internal Medicine Physicians in TX
Which TX internal medicine physicians receive the most from drug and device companies.
By company
Novartis Pharmaceuticals Corporation Payments to Doctors
See all physicians who received payments from Novartis Pharmaceuticals Corporation.
By company
E.R. Squibb & Sons, L.L.C. Payments to Doctors
See all physicians who received payments from E.R. Squibb & Sons, L.L.C.
By company
PFIZER INC. Payments to Doctors
See all physicians who received payments from PFIZER INC.
About this page
This page combines public CMS records with calculated summaries and explanatory procedure labels. These transformations are not verbatim federal records. Sources: NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology